Tetrapeptide inhibitors of the glutamate vesicular transporter (VGLUT)

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 18, 2007, Pages 5125-5128

  Patel, Sarjubhai A ^a   Nagy, Jon O ^a   Bolstad, Erin D ^a   Gerdes, John M ^a   Thompson, Charles M ^a  

^a UNIVERSITY OF MONTANA   (United States)

Author keywords

Glutamate; Inhibitor; Tetrapeptides; Trypan blue; Uptake; Vesicle; Vesicular glutamate transporter (VGLUT)

Indexed keywords

PROTEIN INHIBITOR; QUINOLINE 2,4 DICARBOXYLIC ACID; QUINOLINE DERIVATIVE; TETRAPEPTIDE; UNCLASSIFIED DRUG; VESICULAR GLUTAMATE TRANSPORTER;

AMINO ACID SEQUENCE; ARTICLE; CHEMICAL STRUCTURE; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

MODELS, MOLECULAR; OLIGOPEPTIDES; VESICULAR INHIBITORY AMINO ACID TRANSPORT PROTEINS;

EID: 34547895076     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.07.006     Document Type: Article

References (21)

1. Thompson C.M., Davis E., Carrigan C.N., Cox H.D., Bridges R.J., and Gerdes J.M. Curr. Med. Chem. 12 (2005) 2041
2. Fykse E.M., and Fonnum F. Neurochem. Res. 21 (1996) 1053
3. Maycox P.R., Deckwerth T., Hell J.W., and Jahn R. J. Biol. Chem. 263 (1988) 15423
4. Tabb J.S., Kish P.E., Van Dyke R., and Ueda T. J. Biol. Chem. 267 (1992) 15412
5. Wolosker H., de Souza D.O., and de Meis L. J. Biol. Chem. 271 (1996) 11726
6. Cidon S., and Sihra T.S. J. Biol. Chem. 264 (1989) 8281
7. Hartinger J., and Jahn R. J. Biol. Chem. 268 (1993) 23122
8. Bartlett R.D., Esslinger C.S., Thompson C.M., and Bridges R.J. Neuropharmacology 37 (1998) 839
9. Bridges R.J., Lovering F.E., Koch H., Cotman C.W., and Chamberlin A.R. Neurosci. Lett. 174 (1994) 193
10. Garlin A.B., Sinor A.D., Sinor J.D., Jee S.H., Grinspan J.B., and Robinson M.B. J. Neurochem. 64 (1995) 2572
11. Naito S., and Ueda T. J. Neurochem. 44 (1985) 99
12. Bridges R.J., Kavanaugh M.P., and Chamberlin A.R. Curr. Pharm. Des. 5 (1999) 363
13. Keller B.U., Blaschke M., Rivosecchi R., Hollmann M., Heinemann S.F., and Konnerth A. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 605
14. Carrigan C.N., Bartlett R.D., Esslinger C.S., Cybulski K.A., Tongcharoensirikul P., Bridges R.J., and Thompson C.M. J. Med. Chem. 45 (2002) 2260
15. Carrigan C.N., Esslinger C.S., Bartlett R.D., Bridges R.J., and Thompson C.M. Bioorg. Med. Chem. Lett. 9 (1999) 2607
16. 2/HOAc for 3 h. Peptides were treated with TFA to remove protecting groups.
17. 3H-l-glutamate ± inhibitors (0.01-5 mM) to the synaptic vesicles (approx. 0.1 mg protein). Rates of uptake were normalized to protein content
18. Highly lipophilic peptides displayed poor solubility and were first solubilized in acetonitrile and then diluted into the Hepes assay buffer.
19. Carlson M.D., Kish P.E., and Ueda T. J. Biol. Chem. 264 (1989) 7369
20. Altschul S.F., and Koonin E.V. Trends Biochem. Sci. 23 (1998) 444
21. Altschul S.F., Madden T.L., Schaffer A.A., Zhang J., Zhang Z., Miller W., and Lipman D.J. Nucleic Acids Res. 25 (1997) 3389